1 – 10 of 16
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease
(
- Contribution to journal › Article
-
Mark
Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease
(
- Contribution to journal › Article
- 2022
-
Mark
Validation of Plasma Amyloid-β 42/40 for Detecting Alzheimer Disease Amyloid Plaques
(
- Contribution to journal › Article
- 2021
-
Mark
Late-Life Depression Is Associated With Reduced Cortical Amyloid Burden : Findings From the Alzheimer's Disease Neuroimaging Initiative Depression Project
(
- Contribution to journal › Article
-
Mark
The impact of amyloid burden and APOE on rates of cognitive impairment in late life depression
(
- Contribution to journal › Article
- 2018
-
Mark
Chronic depressive symptomatology and CSF amyloid beta and tau levels in mild cognitive impairment
(
- Contribution to journal › Article
-
Mark
Sex-specific genetic predictors of Alzheimer’s disease biomarkers
(
- Contribution to journal › Article
- 2017
-
Mark
Time to amyloid positivity and preclinical changes in brain metabolism, atrophy, and cognition : Evidence for emerging amyloid pathology in alzheimer's disease
(
- Contribution to journal › Article
-
Mark
Cortical Atrophy is Associated with Accelerated Cognitive Decline in Mild Cognitive Impairment with Subsyndromal Depression
(
- Contribution to journal › Article
- 2016
-
Mark
Assessing risk for preclinical β-amyloid pathology with APOE, cognitive, and demographic information
(
- Contribution to journal › Article